Janakiraman, Manickam

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 1,889

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 1,454

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research

Protein Kinase Regulation and GTPase SignalingColorectal Cancer Treatments and Studies

Cited by 290

Somatic mutation of fibroblast growth factor receptor‐3 ( FGFR3 ) defines a distinct morphological subtype of high‐grade urothelial carcinoma

Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology

Bladder and Urothelial Cancer TreatmentsFibroblast Growth Factor Research

Cited by 88